ADC Therapeutics (ADCT) Shares Outstanding (Diluted Average) (2023 - 2026)
ADC Therapeutics' (ADCT) quarterly Shares Outstanding (Diluted Average) came in at $154.1 million in Q1 2026, up 43.79% year-on-year from $107.2 million in Q1 2025, and up 12.97% quarter-over-quarter from $136.4 million in Q3 2025.
ADC Therapeutics (ADCT) Shares Outstanding (Diluted Average) (2023 - 2026) Analysis & Trends
ADC Therapeutics has disclosed Shares Outstanding (Diluted Average) across 4 years of filings, most recently posting $154.1 million for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 92.44 Mn |
| 10 | ADC Therapeutics | 167.24 Mn | -63.76 Mn | 7.33 Mn | 154.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 154.14 Mn |
| Sep 30, 2025 | 136.45 Mn |
| Jun 30, 2025 | 113.74 Mn |
| Mar 31, 2025 | 107.20 Mn |
| Sep 30, 2024 | 104.82 Mn |
| Jun 30, 2024 | 89.12 Mn |
| Mar 31, 2024 | 82.55 Mn |
| Sep 30, 2023 | 81.52 Mn |
| Jun 30, 2023 | 81.14 Mn |